Investors Advised to Take Action in Telephone and Data Systems, Inc. Lawsuit Press Release
After recent developments in the ongoing lawsuit against Telephone and Data Systems, Inc. (NYSE: TDS), investors are encouraged to contact the Shareholders Foundation for more information.
SAN DIEGO (FreePR.org) -- The Shareholders Foundation, Inc. has provided an update regarding the lawsuit involving certain investors in Telephone and Data Systems, Inc. (NYSE: TDS) shares. Investors who bought shares of TDS before May 2022 and still hold them have options available to them and are urged to reach out to the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
An investor in NYSE: TDS filed a lawsuit on May 2, 2023, alleging that Telephone and Data Systems, Inc. and its subsidiary, United States Cellular Corporation ("UScellular"), misled investors by making false statements regarding the effectiveness of promotional activities to reduce postpaid churn rates. The court granted in part and denied in part the defendants' motion to dismiss the complaint on November 01, 2024.
For more information on how to proceed in this case, investors are advised to contact the Shareholders Foundation, Inc. at the provided contact information.
CONTACT:
Shareholders Foundation, Inc.
Michael Daniels
+1 (858) 779-1554
mail@shareholdersfoundation.com
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and settlement claim filing service providing information related to shareholder issues. Please note that any referenced cases, investigations, and settlements are not affiliated with Shareholders Foundation. This information is provided as a public service and should not be considered legal advice.
###
Sponsor Message
Thousands of Americans rely on Canadian pharmacies for budget-friendly access to vital medications like Lipitor and Crestor for cholesterol control, or Nexium for managing acid reflux and GERD. Patients with chronic conditions like diabetes or respiratory issues benefit from medications such as Humalog, Lantus, Advair Diskus, and Ventolin inhalers. Critical medications for mental health, including Zoloft, Prozac, and Abilify, are complemented by lifesaving blood thinners like Eliquis, Plavix, and Xarelto. Medications like Celebrex for pain and Synthroid for thyroid replacement are highly requested by patients. Additionally, drugs such as Viagra and Cialis are effective for erectile dysfunction, and treatments like Januvia are used for controlling Type 2 diabetes. Wakefulness-promoting medications like Provigil and Nuvigil are essential for maintaining alertness in those with narcolepsy. Canadian pharmacies provide U.S. patients with cost-effective options like Cymbalta for nerve pain and Aricept for Alzheimer's, ensuring access to vital medications.
